Johnson & Johnsonvs.Pfizer
JNJ vs PFE · both in Big pharma, part of the Medicine, pharma & life science value chain: Large, diversified pharmaceutical groups with broad portfolios across therapeutic areas.
Johnson & Johnson is about 4.5× larger than Pfizer by market cap; Pfizer trades at the lower P/E (18.5 vs 29.5); year to date, Johnson & Johnson leads (+24.2% vs −2.9%).
Side by side
| JNJ | PFE | |
|---|---|---|
| Market cap | $620B | $138B |
| Price | $256.98 | $24.17 |
| Today | −0.8% | −0.3% |
| Return YTD | +24.2% | −2.9% |
| Return 1Y | +63.0% | −6.2% |
| P/E | 29.5 | 18.5 |
| P/S | 6.4 | 2.2 |
| P/B | 7.6 | 1.5 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
Johnson & JohnsonJNJ
American healthcare group with a large pharmaceutical division (Innovative Medicine) and medtech division (MedTech).
Full JNJ profile →PfizerPFE
Large American pharmaceutical group with a broad portfolio in vaccines, oncology and internal medicine.
Full PFE profile →More comparisons in Big pharma
See where JNJ and PFE sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →